MEI Pharma (MEIP) has released an update. MEI Pharma, Inc. has initiated a flexible funding strategy by striking a Sales Agreement with JonesTrading Institutional Services LLC, enabling the company to
MEI Pharma (MEIP) has released an update. MEI Pharma, Inc. has initiated a flexible funding strategy by striking a Sales Agreement with JonesTrading Institutional Services LLC, enabling the company to
17:35 EST MEI Pharma files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on
Stifel הורידו את מחיר היעד שלהם עבור MEI Pharma מ-8 דולר ל-7 דולר אך עדיין מציעים למשקיעים לשמור על המניות שלהם. הם מצפים לקבלת תוצאות מוקדמות ממחקר על טיפול חדש
Stifel lowered the firm’s price target on MEI Pharma to $7 from $8 and keeps a Hold rating on the shares. Preliminary Phase 1 voruciclib/venetoclax dose-escalation data in relapsed/refractory AML
MEI Pharma (MEIP) is scheduled to report 2nd quarter earnings on 02/08/2024. Regarding Q2 estimates, Wall Street analysts expect MEI Pharma to post earnings of -$1.41 per share. Revenue expectations